- UHRA Home
- Browsing by Author
Browsing by Author "Suckling, Keith E."
Now showing items 1-3 of 3
-
The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Berkhout, Theo; Simon, Helen M.; Patel, Dilip D.; Bentzen, Craig; Niesor, Eric; Jackson, Brian; Suckling, Keith E. (1996-06-25)SR-12813 (tetra-ethyl 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)ethenyl-1,1- bisphosphonate) lowers plasma cholesterol in five species. In this paper we investigate the underlying mechanism using Hep G2 cells. SB-12813 inhibited ... -
SKF 99085 a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, suppresses HMG-CoA reductase and induces LDL receptor activity by a novel mechanism
Berkhout, Theo; Simon, H.; Niesor, Eric; Bentzen, Craig; Suckling, Keith E. (1994-09-15)Poster abstract -
SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis
Berkhout, Theo; Simon, Helen M.; Jackson, Brian; Yates, John; Pearce, Nigel; Groot, Pieter H E; Bentzen, Craig; Niesor, Eric; Kerns, William D.; Suckling, Keith E. (1997-09-01)SR-12813 inhibits cholesterol biosynthesis in Hep G2 cells via an enhanced degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Here we also show that SR-12813 inhibits cholesterol biosynthesis in vivo. ...